- Home
- RKDA vs GRI Comparison
RKDA vs GRI Comparison
Compare RKDA & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RKDA
- GRI
- Stock Information
- Founded
- RKDA 2002
- GRI 2018
- Country
- RKDA United States
- GRI United States
- Employees
- RKDA N/A
- GRI N/A
- Industry
- RKDA Agricultural Chemicals
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- RKDA Industrials
- GRI Health Care
- Exchange
- RKDA Nasdaq
- GRI Nasdaq
- Market Cap
- RKDA 5.8M
- GRI 4.7M
- IPO Year
- RKDA 2015
- GRI N/A
- Fundamental
- Price
- RKDA $5.02
- GRI $1.99
- Analyst Decision
- RKDA
- GRI Strong Buy
- Analyst Count
- RKDA 0
- GRI 2
- Target Price
- RKDA N/A
- GRI $22.50
- AVG Volume (30 Days)
- RKDA 1.6M
- GRI 363.3K
- Earning Date
- RKDA 11-11-2025
- GRI 11-13-2025
- Dividend Yield
- RKDA N/A
- GRI N/A
- EPS Growth
- RKDA N/A
- GRI N/A
- EPS
- RKDA N/A
- GRI N/A
- Revenue
- RKDA $5,407,000.00
- GRI N/A
- Revenue This Year
- RKDA $21.31
- GRI N/A
- Revenue Next Year
- RKDA $28.33
- GRI N/A
- P/E Ratio
- RKDA N/A
- GRI N/A
- Revenue Growth
- RKDA 23.79
- GRI N/A
- 52 Week Low
- RKDA $2.53
- GRI $1.10
- 52 Week High
- RKDA $10.31
- GRI $30.43
- Technical
- Relative Strength Index (RSI)
- RKDA 63.75
- GRI 55.55
- Support Level
- RKDA $3.30
- GRI $1.78
- Resistance Level
- RKDA $5.72
- GRI $2.07
- Average True Range (ATR)
- RKDA 0.55
- GRI 0.11
- MACD
- RKDA 0.17
- GRI -0.02
- Stochastic Oscillator
- RKDA 51.46
- GRI 65.66
About RKDA Arcadia Biosciences Inc.
Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water, and others.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.